Piperacillin, beta-lactam inhibitor plus gentamicin as empirical therapy of a sequential regimen in febrile neutropenia of pediatric cancer patients

Supportive Care in Cancer

Volumn 9, Issue 5, 2001, Pages 372-379

  Fleischhack, G ^a   Schmidt Niemann, M ^a   Wulff, B ^b   Havers, W ^b   Marklein, G ^a   Hasan, C ^a   Bode, U ^a  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Febrile neutropenia; Gentamicin; Piperacillin; Sulbactam; Tazobactam

Indexed keywords

BETA LACTAM ANTIBIOTIC; GENTAMICIN; PIPERACILLIN; SULBACTAM; TAZOBACTAM;

ADOLESCENT; ADULT; ANTIMICROBIAL THERAPY; ARTICLE; CANCER; CANCER PATIENT; CHILD; DISEASE CLASSIFICATION; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL TOXICITY; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT OUTCOME;

ADOLESCENT; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CHILD; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; FEVER; GENTAMICINS; GERMANY; HUMANS; NEOPLASMS; NEUTROPENIA; PENICILLANIC ACID; PENICILLINS; PIPERACILLIN; PROSPECTIVE STUDIES; SULBACTAM; TREATMENT OUTCOME;

EID: 0034925120     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s005200000225     Document Type: Article

References (23)

1. The changing epidemiology of bacteremia in neutropenic children with cancer
2. Carbapenems in clinical practice: A guide to their use in serious infection
3. Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer
4. Empirical treatment of fever in neutropenic children: The role of the carbapenems
5. Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia
6. Piperacillin-tazobactam plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer
7. Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients
8. In vitro efficacy of beta-lactam/beta-lactamase inhibitor combinations against bacteria involved in mixed infections
9. Monotherapy for fever and neutropenia in cancer patients: A randomized comparison of ceftazidime versus imipenem
10. A comparison of outcome from febrile neutropenic episodes in children compared with adults: Results from four EORTC studies
11. Monotherapy with piperacillin/tazobactam versus combination therapy with ceftazidime plus amikacin as an empiric therapy for fever in neutropenic cancer patients
12. Routine chest radiography of children with cancer hospitalized for fever and neutropenia: Is it really necessary?
13. Ceftazidime versus imipenem-cilastin as initial monotherapy for febrile neutropenic patients
14. Piperacillin/tazobactam plus tobramycin versus ceftazidime plus tobramycin as empiric therapy for fever in severely neutropenic patients
15. Piperacillin/tazobactam versus imipenem: A double blind, randomized feasibility study at a major teaching hospital
16. Piperacillin plus amikacin vs. piperacillin plus amikacin plus teicoplanin for empirical treatment of febrile neutropenic patients receiving quinolone prophylaxis
17. Comparative activities of clavulanic acid, sulbactam, and tazobactam against clinically important beta-lactamases
18. Fever and neutropenia in children with cancer: A therapeutic approach related to the underlying disease
19. Management of indwelling central venous catheters in pediatric cancer patients with fever and neutropenia
20. A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in neutropenic patients
21. Randomized prospective study comparing cost-effectiveness of teicoplanin and vancomycin as second-line empiric therapy for infection in neutropenic patients
22. The evolution of the empirical management of fever and neutropenia in cancer patients